asset sale

After selling Focus Diagnostics' products business to DiaSorin for $300 million, Quest now estimates annual revenues of between $7.47 billion and $7.54 billion.

The company said selling this business unit frees it to focus on developing new maternal and fetal health solutions for the US and elsewhere.

Hologic will purchase the assets via its subsidiary Gen-Probe, from which DiagnoCure will repurchase Series A shares worth C$1 million.

Tute will offer interpretation and annotation software from Knome's KnoSys appliance as part of its existing cloud offering but is open to providing a local option for interested clients.

Adstec will assume the business, financial, and human resource commitments of the business and pay Transgenomic $300,000 for stock and inventory related to the business.

True Health made its bid last week in an auction, increasing it from an original $32 million in order to beat out other potential buyers.

An undisclosed buyer has offered between $115 million and $125 million for the POC business and Chinese firm Jinjing Group has officially expressed interest.

If the non-binding proposal falls through, the German firm plans to spin off its molecular diagnostics business into a separate entity.

The latest analysis of CYP2C19 genotyping to guide antiplatelet therapy tries to address cost questions from the vantage of a payor or large healthcare system.

The transaction is part of Genetic Technologies' restructuring of its operations.

 

 

Pages

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.